HQL fund: 11.6% yield at 9.6% NAV discount. Learn risks of gain-funded payouts, biotech concentration & tax impact—see if it fits your income plan.

Investing.com -- The biotechnology sector continues to offer compelling investment opportunities in 2026, with several companies poised for significant growth according to Bank of America analysts.

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

Vertex Pharmaceuticals has just seen its price target move from a previously unspecified level to a new, undisclosed figure.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on January 22, 2026, RBC Capital upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sector Perform to Outperform. Analyst Price Forecast Suggests 8.58% Upside ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $467.35, marking a +1.35% move from the previous day.